Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Imperial College London
With
GlaxoSmithKline
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Diagnosis of relapsed ovarian cancer
Responded to at least on one line of prior platinum based therapy
Relapsed within platinum resistant interval (≤6months)
Eastern Cooperative Oncology Group (ECOG) performance status of \<2
Measurable disease defined as a lesion that can be accurately measured in at least one dimension with the longest diameter ≥25mm using conventional techniques
Satisfactory baseline haematologic and organ function:
* Haematologic: Absolute neutrophil count \> or = 1.5 X 10\^9/L; Platelets \> or = 100 X 10\^9/L; Haemoglobin \> or = 9g/dL; PT or INR \< or = 1.2 x ULN; PTT \< or = 1.2 x ULN
* Hepatic: Bilirubin \< or = 1.5 X ULN; AST or ALT \< or = 2.5 X ULN
* Renal: Serum creatinine \< or = 1.5 mg/dL; Or if \>1.5 mg/dL, calculated creatinine clearance \> or = 50mL/min; UPC \<1
You may not be if
Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg\]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be \<140/90 mmHg in order for a subject to be eligible for the study.
Treatment with any of the following anti-cancer therapies:
* radiation therapy 28 days prior to the first dose of pazopanib OR
* surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR
* chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
Treatment with anti-angiogenic therapy
Presence of gross ascites
Clinically significant peripheral neuropathy
Females of childbearing potential who are unwilling to avoid pregnancy, for the duration of the study
Clareo Health | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
